Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

Stanford University1 site in 1 country99,999 target enrollmentAugust 2003

ConditionsProstatic Neoplasms

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Prostatic Neoplasms
Sponsor: Stanford University
Enrollment: 99999
Locations: 1
Primary Endpoint: PSA response that achieves a stable nadir over time.
Status: Completed
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.

Registry

clinicaltrials.gov

Start Date

August 2003

End Date

July 2009

Last Updated

15 years ago

Study Type

Interventional

Study Design

Single Group

Sex

Male

Investigators

Sponsor

Stanford University

Eligibility Criteria

Inclusion Criteria

•Eligible patients will have clinical stage T1c through T2b, initial PSA level \<10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved.
•Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
•Adult men will be considered.
•No life expectancy restrictions will apply.
•Performance Status will not be considered.
•No requirements for organ or marrow function will be made
•Ability to understand and the willingness to sign a written informed consent document.